

□ CSE (<https://thecse.com/en/listings/life-sciences/nova-mentis-life-science-corp>) | OTC (<https://www.otcmarts.com/stock/NMLSF/quote>) | FSE (<https://www.boerse-frankfurt.de/equity/nova-mentis-li-sc-corp>)

[Nova Mentis Files U.S. Patent Application for Psilocybin-Based Therapeutics \(https://novamentis.ca/news/2021/07/29/nova-mentis-files-u-s-patent-application-therapeutics/\)](https://novamentis.ca/news/2021/07/29/nova-mentis-files-u-s-patent-application-therapeutics/)

July 29, 2021 5:00 am Published by Nova Mentis Life Science Corp. (<https://novamentis.ca/news/author/adfsdhrfvvh/>)



Vancouver, British Columbia – July 29, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: NMLSF) (“NOVA” or the “Company”), a biopharmaceutical company focused on developing psilocybin-based therapeutics and complementary diagnostics for neuroinflammatory disorders, is pleased to announce it has filed a U.S. provisional patent application for the production of psilocybin and tryptamine analogues, baeocystin and aeruginascin.

“NOVA is developing a novel, proprietary synthetic drug pipeline, and our provisional U.S. patent application is an important step forward on our pathway to commercialize these products. We are proud and excited about the technology NOVA has developed in conjunction with our API manufacturing partner and believe we have a great opportunity to help treat chronic neuroinflammatory disorders, including autism spectrum disorder (ASD),” says Will Rascan, NOVA’s CEO & President.

Psilocybin, baeocystin and aeruginascin are active compounds within mushrooms that at even at low doses can produce psychoactive effects. The levels of these compounds are typically 1.0% of their dry weight and it is not practical to obtain meaningful pure amounts of these compounds from the flesh of mushrooms, at a reasonable cost, to commercialize these products. The proprietary manufacturing process owned by NOVA will allow the company to totally control its future as it moves to meet regulatory guidelines for clinical studies. NOVA has placed itself in a position to create a wholly owned Drug Master file (DMF) that contains confidential information on the manufacturing, processing and packaging of human drugs. The information contained within the DMF may be used to support an Investigational New Drug application.

“The ability to produce these three psychedelically active tryptamine derivatives in greater than 98 per cent purity places NOVA in a unique position to create a novel formulation for the treatment of autism spectrum disorder (ASD), a complex multidimensional problem with many subsets,” stated Dr. Marvin S. Hausman MD, Chairman of NOVA’s Scientific Advisory Board. “We are pleased to announce our first entourage formulation in the 3rd – 4th quarter 2021, in the same fragile X rat model that the company recently used to reveal significant behavioural improvement with our first drug.”

About Nova Mentis Life Science Corp.

Nova Mentis Life Science Corp. is a Canadian-based biotechnology company and global leader in developing diagnostics and psilocybin-based therapeutic products to diagnose and treat debilitating chronic conditions that have unmet medical needs, such as autism spectrum disorder (ASD) and Fragile X Syndrome (FXS).

For further information on the Company, please visit <https://www.novamentis.ca> (<https://www.novamentis.ca/>) or email info@novamentis.ca (<mailto:info@novamentis.ca>)

On Behalf of the Board

Will Rascan, President & CEO

Nova Mentis Life Science Corp.

Phone: 778-819-0244

Toll Free: 1-833-542-5323

Twitter: @novamentislc

Instagram: @novamentislc

Facebook: @novamentislc

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts re-

This news release contains statements that constitute “forward-looking statements.” Such forward looking statements involve known and unknown risks, uncertainties and other factors that may cause Nova Mentis Life Science’s actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements contained in these forward-looking statements. Forward looking statements are statements that are not historical facts and are generally, but not always, identified by the words “estimates,” “projects,” “potential” and similar expressions, or that events or conditions “will,” “would,” “may,” “could” or “should” occur.

[_\(/#facebook\)](#). [_\(/#twitter\)](#). [_\(/#linkedin\)](#). [_\(/#email\)](#).

<https://www.addtoany.com/share?url=https%3A%2F%2Fnovamentis.ca%2Fnews%2Fmentis-files-u-s-patent-application-for-psilocybin-based-therapeutics%2F&title=Nova%20Mentis%20Files%20U.S.%20Patent%20Application%20Based%20Therapeutics>

[Back to News](#)

To search, type and hit enter

Corporate Head Office

Phone: [778-819-0244](tel:778-819-0244) (<tel:7788190244>)

Toll Free: 1-833-542-5323

Email: info@novamentis.com

Transfer Agent: Computershare

Tel: [604-661-9400](tel:604-661-9400) (<tel:6046619400>)

Auditor: Smythe LLP

Tel: [604-687-1231](tel:604-687-1231) (<tel:6046871231>)

Legal Counsel: Richards Buell Sutton LLP

Tel: [604-682-3664](tel:604-682-3664) (<tel:604-682-3664>)

<https://www.rbs.ca/> (<https://www.rbs.ca/>)

Contact Us

Address:

700-838 West Hasting Street Vancouver, B.C. Canada
V6C 0A6

Phone number:

778-819-0244

Toll Free:

1-833-542-5323

E-mail:

info@novamentis.ca

Follow Us

    <https://www.youtube.com/channel/UCXD1Nhg8ihg2K6obL3->
<https://www.facebook.com/novamentis>
<https://twitter.com/novamentis>
<https://www.linkedin.com/company/novamentis>

Latest from Twitter

Tweets by [@NovaMentisLSC](#)



Nova Mentis Life Science Corp.
[@NovaMentisLSC](#)

We're excited to announce that Nova Mentis has filed a U.S. provisional patent application for a proprietary manufacturing process for the production of [#psilocybin](#) and tryptamine analogues, [#baeocystin](#) & [#aeruginascin](#). bit.ly/3laQxau \$NOVA \$NMLSF [#psychedelicresearch](#)



2h

Subscribe

Subscribe to our mailing list

WEBSITE
POWERED BY
100%
RENEWABLE
ENERGY

<https://whc.ca/green-powered/?aff=3153&gbid=3en>